Prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with coronary heart disease in Xinjiang, China.
ATP Binding Cassette Transporter, Subfamily B
/ blood
Aged
Alleles
Apolipoproteins
/ blood
China
/ epidemiology
Coronary Disease
/ blood
Dyslipidemias
/ blood
Ethnicity
Female
Genotype
Humans
Liver-Specific Organic Anion Transporter 1
/ blood
Male
Middle Aged
Models, Statistical
Polymorphism, Genetic
Prevalence
Retrospective Studies
ABCB1
SLCO1B1
coronary heart disease
dyslipidemia
ethnic
lipid
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
25 Sep 2021
25 Sep 2021
Historique:
received:
28
06
2021
accepted:
06
09
2021
entrez:
26
9
2021
pubmed:
27
9
2021
medline:
22
2
2022
Statut:
epublish
Résumé
Dyslipidemia is a predisposing factor for coronary heart disease (CHD). High-intensity statin therapy is recommended as secondary prevention. ABCB1 and SLCO1B1 genes influence the efficacy and safety of statins. Xinjiang is a multi-ethnic area; however, little is known about the prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in minority groups with CHD. To measure levels of lipid and apolipoprotein and the prevalence of dyslipidemia and gene polymorphisms of ABCB1, SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with CHD in Xinjiang. This descriptive retrospective study compares lipid levels in ethnic groups using Kruskal-Wallis test or analysis of variance. The study compared gene polymorphisms and the prevalence of dyslipidemia among different ethnic groups using the chi-square test. The lipid profiles in plasma were measured before lipid-lowering therapy using commercially available kits. Genotyping of SLCO1B1 and ABCB1 variants was performed using sequencing by hybridization. A total of 2218 patients were successfully screened, including 1044 Han, 828 Uygur, 113 Kazak, 138 Hui, 39 Tatar, 36 Kirgiz, and 20 Sibe patients. The overall mean age was 61.8 ± 10.8 years, and 72.5% of participants were male. Dyslipidemia prevalence in these ethnic groups was 42.1, 49.8, 52.2, 40.6, 48.7, 41.7, and 45.0%, respectively. The prevalence of dyslipidemia, high total cholesterol (TC), high triglycerides (TG), and high low density lipoprotein cholesterol (LDL-C) differed significantly among the groups (P = 0.024; P < 0.001; P < 0.001; P < 0.001, respectively). For the Han group, high LDL-C, high TC, and high TG prevalence differed significantly by gender (P = 0.001, P = 0.022, P = 0.037, respectively). The prevalence of high TC, high TG, and low high density lipoprotein cholesterol (HDL-C) differed significantly by gender in the Uygur group (P = 0.006, P = 0.004, P < 0.001, respectively). The prevalence of high TC in Hui patients significantly differed by gender (P = 0.043). These findings suggest that polymorphisms in ABCB1 and C3435T differ significantly across ethnicities (P < 0.001). The prevalences of dyslipidemia, high TC, high TG, and high LDL-C in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe CHD patients in Xinjiang differed concerning ethnicity. Ethnic, gender, and lifestyle were the key factors that affected the lipid levels of the population. The prevalence of polymorphisms of ABCB1 and C3435T significantly differed across ethnicities. These findings will aid the selection of precision lipid-lowering medications and prevention and treatment of CHD according to ethnicity in Xinjiang.
Sections du résumé
BACKGROUND
BACKGROUND
Dyslipidemia is a predisposing factor for coronary heart disease (CHD). High-intensity statin therapy is recommended as secondary prevention. ABCB1 and SLCO1B1 genes influence the efficacy and safety of statins. Xinjiang is a multi-ethnic area; however, little is known about the prevalence of dyslipidemia and gene polymorphisms of ABCB1 and SLCO1B1 in minority groups with CHD.
OBJECTIVE
OBJECTIVE
To measure levels of lipid and apolipoprotein and the prevalence of dyslipidemia and gene polymorphisms of ABCB1, SLCO1B1 in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe populations with CHD in Xinjiang.
METHODS
METHODS
This descriptive retrospective study compares lipid levels in ethnic groups using Kruskal-Wallis test or analysis of variance. The study compared gene polymorphisms and the prevalence of dyslipidemia among different ethnic groups using the chi-square test. The lipid profiles in plasma were measured before lipid-lowering therapy using commercially available kits. Genotyping of SLCO1B1 and ABCB1 variants was performed using sequencing by hybridization.
RESULTS
RESULTS
A total of 2218 patients were successfully screened, including 1044 Han, 828 Uygur, 113 Kazak, 138 Hui, 39 Tatar, 36 Kirgiz, and 20 Sibe patients. The overall mean age was 61.8 ± 10.8 years, and 72.5% of participants were male. Dyslipidemia prevalence in these ethnic groups was 42.1, 49.8, 52.2, 40.6, 48.7, 41.7, and 45.0%, respectively. The prevalence of dyslipidemia, high total cholesterol (TC), high triglycerides (TG), and high low density lipoprotein cholesterol (LDL-C) differed significantly among the groups (P = 0.024; P < 0.001; P < 0.001; P < 0.001, respectively). For the Han group, high LDL-C, high TC, and high TG prevalence differed significantly by gender (P = 0.001, P = 0.022, P = 0.037, respectively). The prevalence of high TC, high TG, and low high density lipoprotein cholesterol (HDL-C) differed significantly by gender in the Uygur group (P = 0.006, P = 0.004, P < 0.001, respectively). The prevalence of high TC in Hui patients significantly differed by gender (P = 0.043). These findings suggest that polymorphisms in ABCB1 and C3435T differ significantly across ethnicities (P < 0.001).
CONCLUSIONS
CONCLUSIONS
The prevalences of dyslipidemia, high TC, high TG, and high LDL-C in Han, Uygur, Kazak, Hui, Tatar, Kirgiz, and Sibe CHD patients in Xinjiang differed concerning ethnicity. Ethnic, gender, and lifestyle were the key factors that affected the lipid levels of the population. The prevalence of polymorphisms of ABCB1 and C3435T significantly differed across ethnicities. These findings will aid the selection of precision lipid-lowering medications and prevention and treatment of CHD according to ethnicity in Xinjiang.
Identifiants
pubmed: 34563206
doi: 10.1186/s12944-021-01544-3
pii: 10.1186/s12944-021-01544-3
pmc: PMC8466639
doi:
Substances chimiques
ABCB1 protein, human
0
ATP Binding Cassette Transporter, Subfamily B
0
Apolipoproteins
0
Liver-Specific Organic Anion Transporter 1
0
SLCO1B1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
116Subventions
Organisme : natural science foundation of xinjiang province
ID : 2018D01C108
Organisme : tianshan district science and technology foundation of urumqi
ID : T2017-07
Informations de copyright
© 2021. The Author(s).
Références
Can J Physiol Pharmacol. 2020 Jan;98(1):15-22
pubmed: 31574240
Circulation. 2001 Dec 18;104(25):3046-51
pubmed: 11748098
JAMA. 2004 Mar 3;291(9):1071-80
pubmed: 14996776
JAMA. 2007 Jul 18;298(3):309-16
pubmed: 17635891
Pharmacol Rev. 2011 Mar;63(1):157-81
pubmed: 21245207
Medicine (Baltimore). 2020 Jul 17;99(29):e20582
pubmed: 32702814
Pharmacogenet Genomics. 2014 Jan;24(1):43-51
pubmed: 24263182
Anticancer Drugs. 2007 Feb;18(2):111-26
pubmed: 17159598
Intern Emerg Med. 2019 Jun;14(4):621-625
pubmed: 30929131
Circulation. 2002 Dec 17;106(25):3143-421
pubmed: 12485966
Genet Mol Res. 2014 Apr 03;13(2):2385-93
pubmed: 24781993
Circulation. 2007 Jan 30;115(4):450-8
pubmed: 17190864
Int J Clin Pharmacol Ther. 2010 Jan;48(1):36-45
pubmed: 20040338
J Cardiovasc Med (Hagerstown). 2021 Mar 1;22(3):151-161
pubmed: 32858625
Prog Cardiovasc Dis. 2020 Jul - Aug;63(4):503-509
pubmed: 32353373
J Pers Med. 2014 Mar 27;4(2):147-62
pubmed: 25563221
J Cell Physiol. 2018 Apr;233(4):2966-2981
pubmed: 28608522
J Proteome Res. 2019 Jun 7;18(6):2397-2410
pubmed: 30887811
Lab Invest. 2016 Jul;96(7):708-18
pubmed: 27183204
Eur Heart J. 1997 Feb;18(2):235-41
pubmed: 9043839
Pharmacogenomics. 2009 Nov;10(11):1743-51
pubmed: 19891551
Anatol J Cardiol. 2019 Nov;22(5):240-249
pubmed: 31674929
Int J Cardiol. 2018 Jun 1;260:196-203
pubmed: 29622441
Clin Pharmacol Ther. 2005 Aug;78(2):154-67
pubmed: 16084850
JAMA. 2020 Nov 24;324(20):2069-2075
pubmed: 33231670
Am J Cardiol. 2013 May 15;111(10):1415-9
pubmed: 23433768
J Clin Lipidol. 2011 Mar-Apr;5(2):91-6
pubmed: 21392722
Lancet. 2019 Dec 14;394(10215):2173-2183
pubmed: 31810609
Lipids Health Dis. 2020 Apr 14;19(1):73
pubmed: 32290855
Nat Rev Cardiol. 2011 Sep 20;8(11):630-43
pubmed: 21931361
Circulation. 2014 May 6;129(18):1821-31
pubmed: 24622385
Eur Heart J. 2020 Jun 21;41(24):2275-2284
pubmed: 31111151
Int J Clin Exp Med. 2015 Sep 15;8(9):16520-7
pubmed: 26629179
Lancet. 2005 Nov 5;366(9497):1640-9
pubmed: 16271645
Circulation. 2012 Aug 28;126(9):1110-20
pubmed: 22927473
Am J Cardiol. 2012 Jun 15;109(12):1700-4
pubmed: 22440123
Biosci Rep. 2019 Feb 26;39(2):
pubmed: 30696703
J Clin Pharm Ther. 2018 Oct;43(5):647-655
pubmed: 29575099
Pharmazie. 2017 May 1;72(5):288-295
pubmed: 29441875
Lipids Health Dis. 2020 Aug 6;19(1):181
pubmed: 32762692
Pharmacol Rep. 2016 Apr;68(2):476-82
pubmed: 26922556
Circ J. 2013;77(12):2851-9
pubmed: 24240435
Can J Cardiol. 2021 Aug;37(8):1129-1150
pubmed: 33781847
Ann Intern Med. 2017 Dec 5;167(11):ITC81-ITC96
pubmed: 29204622
Circulation. 2016 Nov 22;134(21):1651-1654
pubmed: 27756782
J Am Coll Cardiol. 2009 Oct 20;54(17):1609-16
pubmed: 19833260
Medicine (Baltimore). 2019 Sep;98(36):e17013
pubmed: 31490384
Pharmacogenet Genomics. 2017 Jan;27(1):27-38
pubmed: 27787353
Pharmacogenomics. 2013 Aug;14(11):1283-94
pubmed: 23930675
Curr Opin Lipidol. 2004 Aug;15(4):433-8
pubmed: 15243216